Latest Life Sciences News

Microba Life Sciences is targeting a $6 million capital raise through a $1 million Securities Purchase Plan and a $5 million Placement, both subject to shareholder approval. The funds aim to accelerate diagnostics growth and develop a new testing product.

Vitrafy Life Sciences has launched a non-underwritten Share Purchase Plan to raise approximately A$2 million, offering existing Australian and New Zealand shareholders the chance to buy shares at A$2.60 each, matching the recent institutional placement price.

Charter Hall Social Infrastructure REIT (CQE) has acquired a 25% interest in a $53 million Brisbane pathology lab leased to Sonic Healthcare under a 20-year triple-net lease, while divesting early learning assets and reaffirming FY26 guidance.

Vita Life Sciences projects a slight increase in H1 2026 sales and stable pre-tax profits, supported by strong markets in Australia and Malaysia/Singapore but offset by regulatory headwinds in China.

Microba Life Sciences secures $5 million in a placement led by Sonic Healthcare to fund its push towards cashflow break-even by 2027, backed by strong diagnostic sales and AI-driven efficiencies.

Vitrafy Life Sciences has secured A$30 million through an institutional placement to ramp up manufacturing of its Guardion cryopreservation devices and expand US sales operations, with an additional A$2 million sought via a shareholder plan.

ReNerve has appointed J4 Biologics as a second manufacturer for its Empliq range to meet growing hospital approvals and market demand, strengthening its supply chain and scaling production capacity.

Microba Life Sciences has voluntarily suspended trading of its shares from 5 June 2026, ahead of a material capital raise and an update on its path to break even, expected by 11 June.

Vitrafy Life Sciences has teamed up with Vitalant Innovation Center to tackle the impending gap in red blood cell cryopreservation technology in the US, aiming to replace soon-to-be-discontinued legacy methods and potentially expand into other blood products.

Xenitra Limited has locked in a four-year exclusive distribution agreement for Biomiq Skincare in Greater China, targeting $5 million in minimum purchases and integrating the brand into its blockchain tokenised sales ecosystem.

AnteoTech has locked in an underwriting deal to guarantee up to $7.5 million from the exercise of listed options, potentially raising as much as $10 million before costs.

Cryosite Limited delivered a robust 22% revenue increase and 28% EBITDA growth for the ten months to April 2026, powered by expanding clinical trial activity and infrastructure upgrades.